SCHEMBL23892009

SCHEMBL23892009

CCCC(NC)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.41
UTS2R Q9UKP6 4/20 0.40
MEN1 O00255 5/20 0.39
KMT2A Q03164 5/20 0.39
LMNA P02545 4/20 0.39
SLC6A4 P31645 4/20 0.39
CYP3A4 P08684 3/20 0.39
NPC1 O15118 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C19 P33261 2/20 0.39
MTOR P42345 2/20 0.39
RAB9A P51151 2/20 0.39
SLC6A2 P23975 2/20 0.39
HTR2C P28335 2/20 0.39
SLC6A3 Q01959 2/20 0.39
KDM4E B2RXH2 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8286104 0.85 PDE2A (0.43) PDE2AUTS2RMEN1KMT2ALMNA
SCHEMBL3595285 0.84 UTS2R (0.42) PDE2AUTS2RMEN1KMT2ASLC6A4
SCHEMBL172624 0.80 TAS1R3 (0.48) MEN1KMT2ALMNASLC6A4CYP3A4
SCHEMBL11625671 0.80 TAAR1 (0.41) PDE2AUTS2RMEN1KMT2ALMNA
SCHEMBL31137199 0.77 PDE2A (0.39) PDE2AUTS2RMEN1KMT2ALMNA
SCHEMBL16976289 0.77 PDE2A (0.46) PDE2AMEN1KMT2ALMNASLC6A4
SCHEMBL27634082 0.76 UTS2R (0.40) PDE2AUTS2RMEN1KMT2ALMNA
SCHEMBL2090318 0.76 PDE2A (0.49) PDE2ALMNASLC6A4CYP3A4CYP2D6
SCHEMBL24528911 0.76 KMT2A (0.39) MEN1KMT2ASLC6A4CYP3A4CYP2D6
SCHEMBL9187166 0.76 PDE2A (0.44) PDE2AMEN1KMT2ASLC6A4CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3177611-B1 OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES NUEVOLUTION AS (DK) 2021-10-06 EP disclosed